Table 1.
Baseline demographic data and treatment outcome of the hepatitis C virus cohort
| Descriptions | n | % | Total |
|---|---|---|---|
| Age (mean, range) | 50.6 (24–67) | 91 | |
| Gender | |||
| Male | 83 | 91.2 | 91 |
| Female | 8 | 8.8 | — |
| Race | |||
| Chinese | 33 | 36.3 | 91 |
| Malay | 45 | 49.5 | — |
| Indian | 13 | 14.3 | — |
| Baseline Viral load | |||
| <400 000 IU/ml | 36 | 39.6 | 91 |
| ≥400 000 IU/ml | 55 | 60.4 | |
| Fibrosis score | |||
| 0–1 | 17 | 18.7 | 91 |
| 2 | 7 | 7.7 | — |
| 3 | 12 | 13.2 | — |
| 4 | 45 | 49.5 | — |
| Not done | 10 | 11.0 | — |
| Cirrhosis | 45 | 49.5 | 91 |
| Child‐Pugh A | 41 | 91.1 | 45 |
| Child‐Pugh B | 4 | 8.9 | — |
| Child‐Pugh C | 0 | 0.0 | — |
| Ascites | 8 | 17.8 | 45 |
| Esophageal varices | 16 | 35.6 | 45 |
| HE | 2 | 4.4 | 45 |
| DAA Therapy | 17 | 18.7 | 91 |
| MELD score (mean, range) | 8 (6–14) | — | — |
| SVR | |||
| PR | 59† | 79.7 | 74 |
| DAA | 15‡ | 88.2 | 17 |
| Overall | 74 | 81.3 | 91 |
†
Seven patients who received PR defaulted treatment.
‡
One patient who received DAA passed away during treatment.
DAA, direct‐acting antivirals; MELD, model of end stage liver disease; PR, pegylated interferon and ribavirin; SVR, sustained virological response.